Program
Axitinib
Also written as “AG-013736”, “axitinib” and “OTX-TKI”.
Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 360 open or running | phase 3since May 7, 2007 | Oct 9, 2003 | none ahead |
| Ocular Therapeutix | 54 open or running | phase 3since Jan 12, 2024 | Jun 1, 2018 | Jan 8, 2027phase 3 · NCT06495918 |
| Arog Pharmaceuticals | 10 open or running | phase 2since Oct 6, 2006 | Oct 6, 2006 | none ahead |
| Merck | 10 open or running | phase 3since Jul 29, 2016 | Jul 29, 2016 | none ahead |
| SFJ Pharma Ltd. II | 10 open or running | phase 3since May 11, 2012 | May 11, 2012 | none ahead |
| Strata Oncology | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: fortrea, Gilead Sciences and sfj-pharmaceuticals-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since Oct 9, 2003.
- Nov 2, 2011Phase 1 study in Advanced Solid TumorsPfizer · NCT01469052 · 36 enrolled · United States
- May 11, 2012SFJ Pharma Ltd. II's first study: phase 3 study in Carcinoma, Renal CellNew to SFJ Pharma Ltd. IISFJ Pharma Ltd. II · NCT01599754 · 724 enrolled · United States, China, France and more
- Nov 26, 2013Phase 1 study in CarcinomaPfizer · NCT01999972 · 50 enrolled · United States, United Kingdom
- May 6, 2014Phase 1 study in Carcinoma, Renal CellPfizer · NCT02133742 · 52 enrolled · United States
- Jan 25, 2016Phase 3 study in Carcinoma, Renal CellPfizer · NCT02684006 · 886 enrolled · United States, Australia, Austria and more
- Jul 29, 2016Merck's first study: phase 3 study in Carcinoma, Renal CellNew to MerckMerck · NCT02853331 · 861 enrolled
- Aug 28, 2017Phase 1 study in Carcinoma, HepatocellularPfizer · NCT03289533 · 22 enrolled · Japan
- Feb 28, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03472560 · 61 enrolled · United States, Hungary, Italy and more
- Jun 1, 2018Ocular Therapeutix's first study: phase 1 study in Neovascular Age-related Macular DegenerationNew to Ocular TherapeutixOcular Therapeutix · NCT03630315 · 29 enrolled · Australia
- Oct 1, 2021Strata Oncology's first study: phase 2 study in NeoplasmsNew to Strata OncologyStrata Oncology · NCT05097599 · 11 enrolled · United States
- Jan 5, 2023Phase 1 study in Non-proliferative Diabetic RetinopathyOcular Therapeutix · NCT05695417 · 21 enrolled · United States
- Jan 12, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationOcular Therapeutix · NCT06223958 · 344 enrolled · United States, Argentina, Puerto Rico
- Jul 3, 2024Phase 3 study in Neovascular Age-related Macular DegenerationOcular Therapeutix · NCT06495918 · 825 enrolled · United States, Argentina, Australia and more
- Mar 31, 2026Phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)Ocular Therapeutix · NCT07516132 · 850 planned · United States
Ahead
- Jan 8, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationOcular Therapeutix · NCT06495918
- Aug 1, 2030Primary completion: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)Ocular Therapeutix · NCT07516132
TargetBeta
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07516132Neovascular Age-Related Macular Degeneration (nAMD) · United States | 3 | Recruiting | Ocular Therapeutix | Aug 1, 2030 | 850 |
| NCT06495918Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more | 3 | Active, not recruiting | Ocular Therapeutix | Jan 8, 2027 | 825 |
| NCT06223958Neovascular Age-Related Macular Degeneration · United States, Argentina, Puerto Rico | 3 | Active, not recruiting | Ocular Therapeutix | Apr 29, 2026 | 344 |
| NCT05695417Non-proliferative Diabetic Retinopathy · United States | 1 | Active, not recruiting | Ocular Therapeutix | Jan 2024 | 21 |
| NCT05097599Neoplasms · United States | 2 | Terminated | Strata Oncology | Jun 12, 2024 | 11 |
| NCT03630315Neovascular Age-related Macular Degeneration · Australia | 1 | Completed | Ocular Therapeutix | Jan 10, 2024 | 29 |
| NCT03472560Carcinoma, Non-Small-Cell Lung · United States, Hungary, Italy and more | 2 | Terminated | Pfizer | Feb 9, 2023 | 61 |
| NCT03289533Carcinoma, Hepatocellular · Japan | 1 | Completed | Pfizer | Aug 27, 2019 | 22 |
| NCT02853331Carcinoma, Renal Cell | 3 | Completed | Merck | Oct 18, 2018 | 861 |
| NCT02684006Carcinoma, Renal Cell · United States, Australia, Austria and more | 3 | Completed | Pfizer | Aug 31, 2023 | 886 |
| NCT02133742Carcinoma, Renal Cell · United States | 1 | Completed | Pfizer | Mar 31, 2017 | 52 |
| NCT01999972Carcinoma · United States, United Kingdom | 1 | Completed | Pfizer | Feb 22, 2017 | 50 |
| NCT01599754Carcinoma, Renal Cell · United States, China, France and more | 3 | Terminated | SFJ Pharma Ltd. II | Oct 10, 2017 | 724 |
| NCT01469052Advanced Solid Tumors · United States | 1 | Completed | Pfizer | Jul 2004 | 36 |
| NCT01441388Carcinoma, Renal Cell | 1 | Withdrawn | Pfizer | Nov 2013 | 0 |
| NCT01210495Carcinoma, Hepatocellular · United States, Belgium, China and more | 2 | Completed | Pfizer | Mar 3, 2014 | 224 |
| NCT01020136Healthy Volunteer · Singapore | 1 | Completed | Pfizer | Feb 2010 | 42 |
| NCT00920816Kidney Neoplasms · United States, Bosnia and Herzegovina, Bulgaria and more | 3 | Completed | Pfizer | Jul 27, 2012 | 492 |
| NCT00919204Healthy Volunteers · China | 1 | Completed | Pfizer | Aug 2009 | 14 |
| NCT00918632Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Jul 2009 | 30 |
| NCT00905814Healthy Volunteers · Singapore | 1 | Completed | Pfizer | Sep 2009 | 60 |
| NCT00842244Stomach Neoplasms · Japan, Korea, Republic of | 1 | Completed | Pfizer | Dec 2009 | 22 |
| NCT00835978Carcinoma, Renal Cell · United States, Czechia, Germany and more | 2 | Completed | Pfizer | Oct 2012 | 213 |
| NCT00828919Solid Tumors · United States, Czechia, France and more | – | Completed | Pfizer | Aug 14, 2023 | 52 |
| NCT00768755Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more | 2 | Completed | Pfizer | Mar 2011 | 180 |
| NCT00735904Carcinoma · Poland, Romania, South Africa and more | 2 | Completed | Pfizer | Nov 2011 | 38 |
| NCT00726752Neoplasms · Japan | 1 | Completed | Pfizer | Apr 2010 | 6 |
| NCT00692341Hepatic Insufficiency · United States | 1 | Completed | Pfizer | Oct 2008 | 24 |
| NCT00678392Kidney Neoplasms · United States, Australia, Austria and more | 3 | Completed | Pfizer | Aug 31, 2010 | 723 |
| NCT00615056Colorectal Neoplasms · United States, Canada, France and more | 2 | Completed | Pfizer | Mar 2011 | 171 |
| NCT00600821Carcinoma, Non-Small-Cell Lung · United States, Czech Republic, France and more | 2 | Completed | Pfizer | Apr 2011 | 118 |
| NCT00569946Carcinoma, Renal Cell · Japan | 2 | Completed | Pfizer | Feb 26, 2010 | 64 |
| NCT00471146Carcinoma, Pancreatic Ductal · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Jan 2009 | 630 |
| NCT00460603Colorectal Neoplasms · United States | 2 | Completed | Pfizer | Apr 2012 | 187 |
| NCT00454649Neoplasms · United States, Poland, Spain | 1 | Completed | Pfizer | Aug 2009 | 102 |
| NCT00447005Carcinoma · Japan | 1 | Completed | Pfizer | Aug 2009 | 12 |
| NCT00389441Thyroid Neoplasms · United States, Canada, China and more | 2 | Completed | Pfizer | Sep 2012 | 52 |
| NCT00386555Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Arog Pharmaceuticals | 0 | |
| NCT00282048Kidney Neoplasms · United States | 2 | Completed | Pfizer | Feb 2009 | 62 |
| NCT00219557Pancreatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Mar 14, 2008 | 111 |
| NCT00094107Melanoma · United States, France | 2 | Completed | Pfizer | Apr 2008 | 32 |
| NCT00094094Lung Neoplasms · United States, Germany | 2 | Completed | Pfizer | Jul 2007 | 32 |
| NCT00094055Thyroid Neoplasms · United States | 2 | Completed | Pfizer | Jan 2009 | 60 |
| NCT00076024Breast Neoplasms · United States, Canada, Czech Republic and more | 2 | Completed | Pfizer | Jan 2007 | 174 |
| NCT00071006Leukemia, Myeloid, Acute · United States | 2 | Completed | Pfizer | Jul 2004 | 12 |
How it is read
Names in the registry
- “AG-013736”, 23 entries
- “axitinib”, 13 entries
- “OTX-TKI”, 8 entries
- “Axitinib (AG-013736)”, 8 entries
- “AG-013736 (axitinib)”, 7 entries
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 8 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Macular Degeneration, 4 studies
- Neoplasms, 3 studies
- Carcinoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.